Stock analysts at Berenberg Bank assumed coverage on shares of Gilead Sciences Inc. (NASDAQ:GILD) in a research note issued on Thursday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, September 14th. Credit Suisse Group AG decreased their price objective on shares of Gilead Sciences from $115.00 to $95.00 and set an “outperform” rating for the company in a report on Wednesday, September 14th. Jefferies Group reiterated a “buy” rating and set a $91.00 price objective on shares of Gilead Sciences in a report on Monday, September 12th. Morgan Stanley set a $100.00 price objective on shares of Gilead Sciences and gave the company a “hold” rating in a report on Tuesday, September 6th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $108.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 31st. Nine equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $105.41.

Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.51% on Thursday, hitting $81.28. 4,684,470 shares of the stock traded hands. Gilead Sciences has a 52-week low of $76.67 and a 52-week high of $111.11. The stock has a market cap of $107.26 billion, a P/E ratio of 7.13 and a beta of 1.06. The stock’s 50 day moving average price is $79.37 and its 200 day moving average price is $85.98.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/gilead-sciences-inc-gild-now-covered-by-berenberg-bank-2.html

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The company earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. During the same quarter last year, the business posted $3.15 EPS. The firm’s revenue for the quarter was down 5.7% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences will post $11.77 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.30%. The ex-dividend date of this dividend is Wednesday, September 14th. Gilead Sciences’s payout ratio is 16.56%.

In related news, EVP Paul Rutherford Carter sold 2,000 shares of the company’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $83.12, for a total value of $166,240.00. Following the completion of the sale, the executive vice president now owns 63,122 shares of the company’s stock, valued at $5,246,700.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John F. Milligan sold 70,000 shares of the company’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the completion of the sale, the insider now directly owns 1,128,963 shares of the company’s stock, valued at approximately $87,765,583.62. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Van Hulzen Asset Management LLC raised its stake in shares of Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 100 shares in the last quarter. Joel Isaacson & Co. LLC raised its stake in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 226 shares in the last quarter. Roble Belko & Company Inc raised its stake in shares of Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,035 shares in the last quarter. Pinkerton Retirement Specialists LLC raised its stake in shares of Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 1,582 shares in the last quarter. Finally, Jolley Asset Management LLC raised its stake in shares of Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 682 shares in the last quarter. 77.94% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.